MBX Biosciences (MBX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting called to order, minutes recorded by legal counsel, and agenda based on notice and proxy statement mailed to stockholders.
Directors and audit firm representatives introduced; meeting held in accordance with bylaws and Delaware law.
Stockholders entitled to vote as of April 10, 2026, with records available for inspection prior to the meeting.
Voting and question procedures explained, with Inspector of Elections appointed and polls opened at 8:03 A.M.
Board and executive committee updates
Two nominees, Patrick J. Heron and Edward T. Mathers, put forward for election as Class II directors to serve until 2029.
No stockholder nominations received; board unanimously recommends voting in favor.
Corporate governance
Audit committee, comprised entirely of independent directors, appointed Ernst & Young LLP as independent auditor for 2026.
Board submits auditor ratification to stockholders as a matter of good governance, though not required by bylaws.
Latest events from MBX Biosciences
- Q2 net loss rose to $37.1M as R&D spending increased; cash reserves support operations into 2029.MBX
Q2 2026 - Advancing precision peptide therapies for endocrine and obesity indications with strong clinical momentum.MBX
Corporate presentation - Phase III for once-weekly canvuparatide starts Q3 2024, with major 2026 data and strong financials.MBX
Piper Sandler 37th Annual Healthcare Conference - Once-weekly canvuparatide showed durable efficacy and safety at one year, supporting Phase III advancement.MBX
Study result - Advancing once-weekly and monthly therapies for obesity and hypoparathyroidism with key data ahead.MBX
Jefferies Global Healthcare Conference 2026 - Once-monthly MBX 4291 achieved 7% weight loss and strong tolerability in phase I.MBX
Status update - Audit Committee and board changes, plus new consulting agreement with equity awards.MBX
Proxy filing - Q1 2026 net loss narrowed, $440M cash runway into 2029, and Phase 3 trial prep advanced.MBX
Q1 2026 - Vote on two director elections and auditor ratification at the June 2026 virtual meeting.MBX
Proxy filing